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Abstract 
Aim Dental biofilms are complex communities composed 
largely of harmless bacteria. Certain pathogenic species 
including Streptococcus mutans (S. mutans) can become 
predominant when host factors such as dietary sucrose 
intake imbalance the biofilm ecology. Current approaches 
to control S. mutans infection are not pathogen-specific and 
eliminate the entire oral community along with any 
protective benefits provided. Here, we tested the hypothesis 
that removal of S. mutans from the oral community 
through targeted antimicrobial therapy achieves protection 
against subsequent S. mutans colonization. 
Methodology Controlled amounts of S. mutans were 
mixed with S. mutans-free saliva, grown into biofilms and 
visualized by antibody staining and cfu quantization. Two 
specifically-targeted antimicrobial peptides (STAMPs) 
against S. mutans were tested for their ability to reduce S. 
mutans biofilm incorporation upon treatment of the inocula. 
The resulting biofilms were also evaluated for their ability  
to resist subsequent exogenous S. mutans colonization. 
Results S. mutans colonization was considerably reduced 
(9 ± 0.4 fold reduction, P=0.01) when the surface was 
preoccupied with saliva-derived biofilms. Furthermore, 
treatment with S. mutans-specific STAMPs yielded S. 
mutans-deficient biofilms with significant protection against 
further S. mutans colonization (5 minutes treatment: 38 ± 13 
fold reduction P=0.01; 16 hours treatment: 96 ± 28 fold 
reduction P=0.07). 
Conclusion S. mutans infection is reduced by the pre- 
sence of existing biofilms. Thus maintaining a healthy or 
“normal” biofilm through targeted antimicrobial therapy 
(such as the STAMPs) could represent an effective strategy 
for the treatment and prevention of S. mutans colonization 
in the oral cavity and caries progression. 
Keywords  targeted antimicrobial therapy, antimicrobial 
peptide, biofilm, Streptococcus mutans, protective coloni- 
zation, caries 






Dental caries (tooth decay) is one of the most 
prevalent and costly diseases in the United States 
and throughout the world (Evans and Kleinman, 
2000). Although the ultimate manifestation of the 
disease is the dissolution of tooth structure, the 
biological nature of the disease is a microbial 
infection caused primarily by the cariogenic bacte- 
rium Streptococcus mutans (S. mutans) (Clarke, 
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1924; Loesche et al., 1975; Loesche, 1986; Tanzer 
et al., 2001). Most current dental therapies are 
focused on eradicating the entire dental plaque via 
mechanical removal or broad-spectrum antimic- 
robial treatments. However, the improved under- 
standing of oral microbial ecology, especially the 
importance of the balance between oral pathogens 
and commensal residents, has prompted interest in 
novel approaches focused on selective pathogen 
inhibition and modulation of the microbial com- 
position of dental plaque to control pathogenesis.   
Most of these new approaches aim to achieve 
the eradication of S. mutans by targeting its 
virulence factors, such as the colonization of the 
tooth surface via both sucrose dependent and 
independent adhesion mechanisms (Koga et al., 
2002; Smith, 2002), cell-cell signaling (Lonn- 
Stensrud et al., 2007), or acid production. Nume- 
rous approaches include the development of anti- 
caries vaccines against either cell surface antigens 
(Abiko, 2000) or a glucosyltransferase enzyme 
that is responsible for glucan production (Xu et al., 
2007). In an effort to reduce acid production of 
naturally occurring S. mutans, replacement therapy 
using a genetically engineered S. mutans that is 
able to outcompete indigenous strains while pro- 
ducing significantly less acid has been attempted 
(Hillman et al., 2000). Several recent studies have 
also focused on understanding the interactions 
between S. mutans and other neighboring strepto- 
cocci in the dental plaque and their impact on S. 
mutans pathogenesis. For example, S. sanguinis 
and S. oligofermentans have been observed to 
inhibit S. mutans growth through hydrogen peroxide 
production (Kreth et al., 2005; Tong et al., 2007; 
Kreth et al., 2009).  
Our research group has initiated a targeted 
approach to control oral microbial pathogenesis 
via a new class of antimicrobials, called speci- 
fically-targeted antimicrobial peptides (STAMPs) 
(Eckert et al., 2006). A typical STAMP molecule 
consists of two functionally independent moieties 
conjoined in a linear peptide sequence: a non- 
specific antimicrobial peptide serves as the killing 
moiety while a species-specific binding peptide 
comprises the targeting moiety that provides speci- 
fic binding to a selected pathogen and facilitates 
the targeted delivery of the attached antimicrobial 
peptide. STAMPs have shown effective elimination 
of S. mutans from a mixed-species environment 
without affecting closely related non-cariogenic 
oral streptococci (Eckert et al., 2006). Based on 
these features, STAMPs have a strong potential for 
development into novel therapeutics that may 
selectively eliminate pathogens while preserving 
the benefits associated with a healthy normal flora.   
In the present study, we used a controlled in 
vitro approach to examine the effect of normal flora 
on S. mutans colonization. In particular, we tested 
the hypothesis that S. mutans-specific STAMPs 
can protect against S. mutans infection by main- 




Materials and Methods 
 
Strains and growth conditions 
S. mutans strains UA140 (Qi et al., 2001) and 
JM11 (UA140::pldh-luc, Spcr) (Merritt et al., 2005) 
were grown anaerobically (N2 85%, H2 10%, and 
CO2 5%) in Todd–Hewitt (TH) medium (Difco) or 
on TH agar plates at 37℃. JM11 was grown in  
TH supplemented with 800 μg⋅mL-1 spectinomycin 
(Sigma, St Louis, USA). For growth of saliva- 
derived biofilms, TH medium was supplemented 
with 1% mannose, 1% sucrose, and 1% dextrose. 
All biofilms were grown anaerobically at 37℃. 
 
Peptide synthesis and purification 
Two STAMPs were used in this study: C16G2 
(Eckert et al., 2006) and 2_1G2, a derivative in 
which the S. mutans-specific CSPC16 targeting 
domain was replaced with the newly identified S. 
mutans-specific targeting peptide 2_1 (FIKHFIHRF). 
Peptides were synthesized using Fmoc (9-fluo- 
renylmethoxy carbonyl) solid-phase chemistry (431A 
peptide synthesizer; Applied Biosciences, Foster 
City, USA) as previously described (Eckert et al., 
2006) and purified to >95% by high-performance 
liquid chromatography (Waters, Milford, USA), as 
described previously (He et al., 2009). Peptide 
mass was determined by electrospray ionization 
(ESI) mass spectrometry (data not shown, 3100 
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Screening of saliva samples using confocal laser 
scanning fluorescence microscopy (CLSM) 
An anti-S. mutans monoclonal antibody was 
employed for detecting S. mutans colonization 
within saliva-derived biofilms, as described pre- 
viously (Gu et al., 2002; Gu et al., 2005). Since 
this approach cannot distinguish endogenous and 
exogenously added S. mutans, individuals were 
screened for saliva that was naturally free of S. 
mutans to enable better controlled experiments. 
For screening, biofilms were grown from unsti- 
mulated saliva samples collected from 12 subjects 
6 hours post-cleaning. Individual saliva samples 
were diluted 1:4 into TH supplemented with 1% 
glucose, 1% mannose and 1% sucrose. This sus- 
pension was subjected to a low speed centri- 
fugation for 10 minutes at 600 × g to remove 
eukaryotic cells and large debris and 400 μL of the 
supernatant was inoculated into each well of a 
sterile 8-well Lab-TekTM Chambered Coverglass 
(Nalge Nunc International; Naperville, USA) that 
had been coated with 50% (filtered microorga- 
nism-free) saliva in phosphate buffered saline 
(PBS, pH 7.0) for pellicle formation. To enhance 
attachment of salivary bacteria, 2 cycles of “starter” 
biofilms were allowed to deposit matrix material 
on the glass surface for 24 hours followed by 
removal and chamber re-sterilization, prior to 
seeding of experimental biofilms. Biofilms were 
incubated for 16 hours prior to staining and 
microscopic evaluation. 
For visualization, biofilms were stained with the 
cell permeant general nucleic acid stain SYTO59 
(Invitrogen, Carlsbad, USA) according to manu- 
facturer’s instructions, and S. mutans was specifi- 
cally identified utilizing SWLA1–IgG2a as described 
previously (Gu et al., 2002; Gu et al., 2005) with 
the following modifications: the primary antibody 
was diluted in PBS to 50 μg⋅mL-1; 100 μL of this 
diluted antibody solution was used for each sample 
and incubated for 30 minutes. Biofilms were then 
washed three times with PBS and further incu- 
bated with fluorescein isothiocyanate (FITC) con- 
jugated goat anti-mouse IgG diluted 1:50 in PBS 
for an additional 30 minutes according to manu- 
facturer’s instructions (Sigma, St Louis, USA). 
Biofilms were examined with a PASCAL 5 
confocal laser scanning microscope using LSM 5 
PASCAL software (Zeiss, Jena, Germany).  The 
scanning module of the system was mounted onto 
an inverted microscope (Axiovert 200M) and 
samples were viewed through a 40 × oil-immersion 
objective (Plan-Neofluar/1.3). Excitation at 488 nm 
with an argon laser in combination with a 505– 
560 nm bandpass emission filter was used for 
FITC fluorescence imaging. An excitation at 633 nm 
with a helium-neon laser and a 650 nm longpass 
emission filter was utilized to reveal SYTO59- 
stained cells within the samples. 
Saliva samples that appeared free of S. mutans 
were further tested for their ability to integrate 
exogenously added S. mutans UA140 upon co- 
inoculation. S. mutans at 1.25×106 cells per well 
was added directly to the processed saliva and 
biofilms were allowed to form for 16 hours prior 
to visualization as described above. Samples without 
detectable S. mutans were eliminated due to their 
potential ability to suppress S. mutans growth. 
Saliva from subjects containing no detectable S. 
mutans that did not inhibit growth of exogenously 
added S. mutans were utilized for further studies. 
 
Confirmation of protective colonization effects 
To test protective biofilm effects, processed 
saliva suspensions were allowed to form biofilms 
for 16 hours and then replenished with fresh 
medium containing 1.25×106 S. mutans cells. After 
an additional 24 hours growth period, samples 
were stained and subjected to CLSM analysis as 
described above or cfu analysis described below. 
 
Evaluation of STAMP ability to inhibit S. mutans 
biofilm incorporation at innoculation 
To test the ability of S. mutans-specific STAMPs 
to remove S. mutans at inoculation, 100 μmol⋅L-1 
of the respective peptide was directly added to  
the mixture of salivary bacteria and JM11 (1.25 
×106 cfu⋅mL-1). The STAMPs would then either be 
left in the inoculum or be removed via an imme- 
diate high speed spin (16 000 × g) for 5 minutes. 
The latter samples were washed once and resus- 
pended in an equal volume of fresh medium prior 
to inoculation. 400 μL of the mixtures were inocu- 
lated into each well of a pellicle-coated and UV 
sterilized 48-well cell culture plate. As bacterial 
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cells attach significantly better to plastic than to 
glass surfaces, the “conditioning” process was 
omitted for these experiments. Biofilms were 
grown anaerobically for 16 hours, and then washed 
with PBS and subject to viability evaluation via 
quantitation of viable colony forming units (cfu) as 
follows: biofilms were mechanically disrupted by 
vigorous pipetting in 1 mL TH and a series of 1:10 
dilutions was plated onto both TH plates and TH 
plates supplemented with 800 µg⋅mL-1 spectino- 
mycin to assess total cell viability and JM11 
viability, respectively.  
 
Evaluation of STAMP-treated  S. mutans-free 
biofilms to inhibit S. mutans incorporation  
An S. mutans JM11 and saliva mixture was 
prepared and treated with the respective STAMPs 
as described above prior to biofilm formation for 
16 hours before and a subsequent challenge with 
1.25×106 JM11 cells in fresh medium. After an 
additional 24 hours of anaerobic incubation, S. 
mutans incorporation was determined by biofilm 






Establishment of a saliva-derived biofilm system 
and observation of protective colonization 
Biofilms were grown with saliva collected from 
subjects who are not colonized by detectable 
levels of S. mutans (selection criteria described in 
Methods) (Figure 1A). To evaluate if we could 
control exogenous S. mutans addition, UA140 was 
inoculated together with the salivary bacteria to 
form biofilms which were then examined for S. 
mutans incorporation. S. mutans became an integral 
part of the biofilm community (Figure 1B), com- 
prising 2.7% ± 1.0% of the total population after 
16 hours of biofilm growth (Figure 1D, 0 hour). 
This finding confirmed that the in vitro saliva- 
derived biofilm model employed in this study 
enables the controlled addition of S. mutans to 
address the ability of this bacterium to invade 
preexisting biofilms. 
Interestingly, the proportion of S. mutans incor- 
porated into the biofilm was significantly reduced 
(0.3% ± 0.1% of the total biofilm population, 
representing 9 ± 0.4 fold reduction P=0.01) when 
S. mutans was added after saliva biofilms were 
allowed to form for 16 hours. Although biofilms 
were grown for an extra 24 hours after addition of 
S. mutans, this further growth period did not 
significantly increase the number of total biofilm 
cells (P=0.14, Figures 1C and 1D). These results 
indicate that the observed difference reflects a 
protective colonization effect when a biofilm is 
already formed prior to addition of S. mutans.    
 
Generation of protective S. mutans-free biofilms 
via STAMP treatment 
The results in Figure 1 suggested that the ability 
of S. mutans to colonize a surface was reduced in 
the presence of a preexisting biofilm derived from 
natural occurring S. mutans-free saliva. Based on 
this finding, we hypothesized that targeted elimi- 
nation of S. mutans could yield a biofilm with 
similar protection capability. Previous studies have 
demonstrated that the STAMP C16G2 possessed 
specific antimicrobial activity against S. mutans 
cells in both planktonic and early stages of mixed 
species biofilm formation (Eckert et al., 2006). 
Here, we evaluated if removal of S. mutans from 
the saliva inoculum with C16G2 or the func- 
tionally analogous STAMP 2_1G2 leads to the 
generation of protective biofilms with the ability 
to prevent secondary surface colonization by this 
cariogenic species.  
Biofilm inocula containing salivary bacteria and 
the spectinomycin-resistant S. mutans derivative 
JM11 were incubated with the STAMPs for 16 
hours. No S. mutans cells were detected in the 
resulting biofilms for both peptide-treated samples, 
while the untreated control contained ~107 S. mutans 
cells in the biofilm. More importantly, these in 
vitro generated S. mutans-free saliva biofilms  
were able to prevent subsequent infection from 
exogenous S. mutans (Figure 2). A striking diffe- 
rence in the degree of colonization prevention was 
apparent in 2_1G2 and C16G2-treated samples:  
a 96 ± 28 fold (P=0.01) and 92 ± 14 fold (P=0.01) 
reduction, respectively, compared to S. mutans levels 
detected in the untreated control (Figure 2). 
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Figure 1  Detection of S. mutans in the saliva derived biofilms 
Saliva containing no detectable S. mutans was chosen for this study. (A)-(C): CLSM imaging. S. mutans cells within the biofilm were 
labeled with anti-S. mutans monoclonal antibody and FITC-conjugated secondary antibody (red). SYTO 59 (green) was used to label the 
total population. (A): 16 hours biofilms derived from saliva. (B): 16 hours biofilms with 1.25×106 S. mutans UA140 cells spiked at 
inoculation. (C): 24 hours saliva biofilm was spiked with 1.25×106 S. mutans cells and allowed to grow for another 16 hours prior to 
staining. (D): Quantification of S. mutans incorporation into saliva biofilm under different growth conditions. 1.25×106 S. mutans strain 
JM11 were added to saliva at 0 hour or 24 hours after inoculation (indicated in the figure). cfu of total biofilm cells and S. mutans cells are 
presented, standard deviation of three independent experiments are shown. 









Figure 2  Evaluation of overnight STAMP treatment 
on S. mutans colonization 
100 µmol⋅L-1 STAMPs were added to a saliva/S. mutans (1.25 
×106) mixture and incubated anaerobically for 16 hours, S. 
mutans surviving cfu were presented (dotted bars). A duplicate 
set of samples were washed and replenished with medium 
containing JM11 cells for additional 24 hours growth. S. mutans 
surviving cfu were presented (grey bars). Standard deviations of 
three independent experiments are shown. 
The overnight treatment with peptides effi- 
ciently enabled growth of S. mutans-free saliva 
biofilms despite the presence of significant numbers 
of S. mutans in the inoculum. Based on these 
encouraging results we further explored the 
STAMPs’ efficacy during shorter exposure times 
that are most relevant for potential therapeutic 
applications. As shown in Figure 3, treatment of an 
S. mutans containing saliva inoculum with either 
STAMP for as little as five minutes prior to 
biofilm growth resulted in biofilms containing 
approximately four- (2_1G2) and five- (C16G2) 
orders of magnitude less S. mutans cells (Figure 3). 
Upon re-infection with S. mutans, 38 ± 13 (2_1G2) 
to 61 ± 13 fold (C16G2) less S. mutans cells were 
detected in treated biofilms compared to the 
untreated control (P=0.07 for both peptides). 
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Figure 3  Evaluation of 5 minutes peptide treat- 
ment on S. mutans colonization 
1.25×106 S. mutans strain JM11 was added to processed 
saliva suspensions and treated with 100 µmol⋅L-1 STAMPs 
for 5 minutes. Samples were washed and then used to 
inoculate overnight biofilms. After 16 hours of growth, 
biofilms were disrupted and plated, S. mutans surviving cfu 
are presented (dotted bars). A duplicate set of samples were 
washed and replenished with medium containing JM11 cells 
for additional 24 hours growth. S. mutans surviving cfu are 
presented (grey bars). Standard deviations of three inde- 





The data presented here support the hypothesis 
that the cariogenic organism S. mutans exhibits 
greatly reduced colonization in the presence of a 
preexisting saliva-derived biofilms containing no 
or a minimal amount of S. mutans. These findings 
provided evidence for the protective effect of a 
“normal” oral biofilm in concurrence with the 
proposed “window of infection” identified based 
on previous clinical studies (Caufield et al., 1993). 
According to this report, S. mutans colonization 
mainly occurs between the second to the third year 
of life. Study participants who were infected 
during this crucial time period acquired persistent 
S. mutans colonization, while uninfected indivi- 
duals remained S. mutans-free until the eruption of 
secondary dentition provided new colonization 
opportunities. It is likely that these uninfected 
individuals formed a protective biofilm community 
void of S. mutans, similar to the ones we observe 
in the in vitro saliva-derived biofilm model system, 
which significantly reduced the ability of S. mutans 
to become part of the biofilm community when 
added later on.   
Though the mechanism behind the ability of 
biofilms to exclude S. mutans remains to be 
elucidated, recent studies by Kreth et al. (Kreth et 
al., 2005; Kreth et al., 2008) demonstrated that the 
sequence of inoculation determines whether cario- 
genic S. mutans or the health-associated S. sanguinis 
(Corby et al., 2005; Corby et al., 2007) compete or 
co-exist with one another. Both species can persist 
in a biofilm when inoculated at the same time, but 
given the chance to establish a biofilm first, either 
species can preclude colonization of the other. In 
the context of this study, it is possible that the 
presence of certain species (such as S. sanguinis) 
in the established biofilms could mediate the 
protective effects against exposure to S. mutans.  
Interestingly, this protective effect was observed 
even in the presence of 1% sucrose in the growth 
medium which, according to the “Ecological Plaque 
Hypothesis” (Marsh, 2003), is likely to give the 
acid-tolerant S. mutans a competitive advantage 
through its ability to produce lactic acid from 
sucrose fermentation. Furthermore, the microbial 
homeostasis within oral biofilms is suggested to 
shift when oral environmental changes, such as the 
ingestion of fermentable sugars, and the creation 
of low pH environments where acid tolerant/gene- 
rating organisms thrive and promote de-minera- 
lization. Given consistent sucrose intake, these 
changes can compound and result in an oral 
biofilm comprised of predominantly cariogenic 
pathogens such as S. mutans. Our results suggest 
that established S. mutans-free biofilms, both natu- 
rally occurring or through STAMP treatment, are 
able to reduce the competitive advantage of S. 
mutans even in the presence of high sugar content, 
thus preventing the shift in the biofilm composi- 
tion toward cariogenesis.  
In addition to demonstrating that prior estab- 
lishment of an S. mutans-free biofilm provides 
considerable protection against subsequent infec- 
tion with this oral pathogen, we were able to 
significantly reduce S. mutans in the inocula with 
short 5 minues exposure, a duration short enough 
for the application of most oral care products.  
More importantly, this reduction in S. mutans load 
achieved via STAMP treatment resulted in bio- 
films with considerable protective effects against 
further S. mutans colonization. Taken together, 
these results suggest that STAMP technology is a 
potentially useful method for removing S. mutans 
Int J Oral Sci, 2(2): 66–73, 2010  - 71 - 
Targeted Antimicrobial Therapy Reduces  Subsequent Colonization     S. mutans Li et al.         http://www.ijos.org.cn
from saliva, thus establishing an oral flora that can 
help prevent or reduce further infection of S. 
mutans.   
STAMP technology is by no means limited to 
modulating oral biofilms. It could potentially extend 
to other simple or complex microbial communities 
where a dynamic shift in microbial diversity is 
required to promote a healthy state for the host. 
Studies have shown that chronic conditions such 
as Crohn’s disease and ulcerative colitis are asso- 
ciated with shifts in the homeostasis of the flora, 
and it is reasonable to speculate that inter-species 
interaction plays a role in determining the disease 
or non-disease state of the complex community 
within the gut as well. STAMP technology could 
be used to remove species that have high occur- 
rence rates in patients suffering these diseases, 
such as Bacteroides vulgatus (Mangin et al., 2004), 
thus helping to reestablish a balanced flora where 
the specific niche of B. vulgatus is filled by other, 
more benign species. Further studies are underway 
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